Tiagabine

Modify Date: 2024-01-03 19:22:59

Tiagabine Structure
Tiagabine structure
Common Name Tiagabine
CAS Number 115103-54-3 Molecular Weight 375.55
Density 1.208 g/cm3 Boiling Point 568ºC at 760 mmHg
Molecular Formula C20H25NO2S2 Melting Point 192oC dec.
MSDS N/A Flash Point 297.3ºC

 Use of Tiagabine


Tiagabine(NO328) is a selective gamma-aminobutyric acid (GABA) reuptake inhibitor.Target: GABA reuptake inhibitorTiagabine had an early onset of effect, as shown by significant reduction from baseline in mean HAM-A total score compared with placebo at week 1 (observed cases, p < .05). Tiagabine was generally well tolerated and not associated with changes in sexual functioning or depressive status. Symptoms of a discontinuation syndrome during taper were not observed. Tiagabine may be a useful treatment option for adult patients diagnosed with GAD [1]. Tiagabine was generally well tolerated; the most common adverse events were nausea, dizziness and headaches [2]. Tiagabine (0.1 microM), an antiepileptic drug that specifically inhibits the GAT-1 GABA transporter inhibited GABA uptake 50% in temporal cortex and 60-68% in white structures [3].

 Names

Name tiagabine
Synonym More Synonyms

 Tiagabine Biological Activity

Description Tiagabine(NO328) is a selective gamma-aminobutyric acid (GABA) reuptake inhibitor.Target: GABA reuptake inhibitorTiagabine had an early onset of effect, as shown by significant reduction from baseline in mean HAM-A total score compared with placebo at week 1 (observed cases, p < .05). Tiagabine was generally well tolerated and not associated with changes in sexual functioning or depressive status. Symptoms of a discontinuation syndrome during taper were not observed. Tiagabine may be a useful treatment option for adult patients diagnosed with GAD [1]. Tiagabine was generally well tolerated; the most common adverse events were nausea, dizziness and headaches [2]. Tiagabine (0.1 microM), an antiepileptic drug that specifically inhibits the GAT-1 GABA transporter inhibited GABA uptake 50% in temporal cortex and 60-68% in white structures [3].
Related Catalog
References

[1]. Pollack, M.H., et al., The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry, 2005. 66(11): p. 1401-8.

[2]. Sheehan, D.V., et al., An open-label study of tiagabine in panic disorder. Psychopharmacol Bull, 2007. 40(3): p. 32-40.

[3]. Henjum, S. and B. Hassel, High-affinity GABA uptake and GABA-metabolizing enzymes in pig forebrain white matter: a quantitative study. Neurochem Int, 2007. 50(2): p. 365-70.

 Chemical & Physical Properties

Density 1.208 g/cm3
Boiling Point 568ºC at 760 mmHg
Melting Point 192oC dec.
Molecular Formula C20H25NO2S2
Molecular Weight 375.55
Flash Point 297.3ºC
PSA 97.02000
LogP 5.78470
Vapour Pressure 9.71E-14mmHg at 25°C
Index of Refraction 1.604
Storage condition -20℃

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TM6128245
CHEMICAL NAME :
3-Piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-, (R)-
CAS REGISTRY NUMBER :
115103-54-3
LAST UPDATED :
199801
DATA ITEMS CITED :
1
MOLECULAR FORMULA :
C20-H25-N-O2-S2.Cl-H
MOLECULAR WEIGHT :
412.04

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
630 mg/kg/21D-I
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
REFERENCE :
EPIRE8 Epilepsy Research. (Elsevier Science Publishers B.V., POB 1527, 1000 BM, Amsterdam, Netherlands) V.1- 1987- Volume(issue)/page/year: 19,205,1994

 Safety Information

Hazard Codes Xi: Irritant;
Risk Phrases R36/37/38
Safety Phrases S26-S36/37-S22
WGK Germany 3

 Synthetic Route

 Synonyms

(-)-(R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid hydrochloride
(R)-(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid
acide (3R)-1-[4,4-bis(3-méthylthiophén-2-yl)but-3-én-1-yl]pipéridine-3-carboxylique chlorhydrate
NO-05-0328
Gabitril / NNC 05-328
Abbott-70569.1
(R)-N-[4,4-di-(3-methylthien-2-yl)but-3-enyl] nipecotic acid hydrochloride
(3R)-1-[4,4-Bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid hydrochloride (1:1)
(3R)-1-[4,4-Bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidin-3-carbonsäurehydrochlorid
TIGABINE
3-Piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-, (3R)-, hydrochloride (1:1)
(R)-1-[4,4-bis(3-methyl-thien-2-yl)-3-butenyl]-3-piperidinecarboxylic acid
(3R)-1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid hydrochloride
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid hydrochloride
TGB
Tiagabine
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid hydrochloride (1:1)
no328
4-bis(3-methyl-2-thienyl)-3-butenyl)-1-((r)-3-piperidinecarboxylicaci
(R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid
(3R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid hydrochloride (1:1)
Abbott-70569.HCl
MFCD00865317
3-piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-, (3R)-, hydrochloride